Real-world treatment patterns and outcomes in ER+/PR+/HER2+metastatic breast cancer (MBC) patients: A National Cancer Database analysis.

被引：2
|
作者：
Statler, Abby
Nahleh, Zeina A.
Hobbs, Brian
Wei, Wei
Gupta, Annie
Blake, Cassann N.
机构：
[1] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
[2] Cleveland Clin Florida, El Paso, TX USA
[3] Cleveland Clin, Lerner Res Inst, Cleveland, OH 44106 USA
[4] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA
[5] Cleveland Clin Florida, Weston, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.1033
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1033
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [41] PRELIMINARY DATA FROM A PROSPECTIVE NON-INTERVENTIONAL STUDY TO CHARACTERIZE REAL-WORLD TREATMENT PATTERNS AND OUTCOMES OF WOMEN WITH ER+/HER2-ADVANCED/METASTATIC BREAST CANCER
    Harbeck, Nadia
    De laurentiis, Michele
    Mitra, Debanjali
    Trantham, Laurel
    Di Virgilio, Roberto
    De Placido, Sabino
    BREAST, 2017, 36 : S48 - S48
  • [42] First-line treatment patterns by age for patients (pts) with HER2+metastatic breast cancer (MBC) in the SystHERs registry
    Jahanzeb, M.
    Tripathy, D.
    Hurvitz, S. A.
    O'Shaughnessy, J.
    Mason, G.
    Yardley, D. A.
    Brufsky, A.
    Rugo, H. S.
    Cobleigh, M.
    Swain, S. M.
    Chu, L.
    Antao, V.
    Yoo, B.
    Kaufman, P. A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [43] Real-world outcomes and safety of pyrotinib in HER2-positive metastatic breast cancer (MBC) patients: A prospective cohort study
    Luo, T.
    Zhang, Q.
    He, P.
    Zhong, X.
    Yan, X.
    Tian, T.
    Huang, J.
    Zhang, Z.
    Zheng, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S490 - S490
  • [44] Real-world use and outcomes of trastuzumab for HER2+metastatic breast cancer in Australia: Analysis of the herceptin program, 2001-2015
    Daniels, Benjamin
    Kiely, Belinda E.
    Lord, Sarah J.
    Houssami, Nehmat
    Pearson, Sallie-Anne
    CANCER RESEARCH, 2018, 78 (04)
  • [45] Serum HER-2 ECD and the efficacy of letrozole in ER+/PR+ metastatic breast cancer: preliminary results of a prospective study.
    Colomer, R
    Llombart, A
    Ramos, M
    Mayordomo, JI
    Fernandez, R
    Tusquets, I
    Barnadas, A
    Gil, M
    Carabantes, F
    Baena, JM
    Ruiz, M
    Palomero, M
    Vera, R
    Munoz, M
    Constenla, M
    Rifa, J
    Ojeda, B
    Calvo, L
    Lloveras, B
    Montero, S
    Alba, E
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 242 - 242
  • [46] Real-world PARPi treatment patterns and outcomes among patients with metastatic breast cancer.
    Dawood, Shaheenah S.
    Brzozowski, Kaylen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] Real-world treatment in patients with HER2+ metastatic breast cancerTreatment decisions in HER2+ mBC
    R. Colomer
    P. Hall
    M. Szkultecka-Debek
    R. C. Bondi
    A. Flinois
    S. Auziere
    J. Y. Le Cléac’h
    Breast Cancer Research and Treatment, 2018, 168 : 197 - 205
  • [48] A real-world registry to evaluate HER2-directed therapy in Australian patients with metastatic breast cancer (MBC).
    Lee, Margaret
    Lok, Sheau Wen
    Turner, Natalie Heather
    Day, Daphne
    Greenberg, Sally
    Green, Michael
    Foo, Serene S.
    Yip, Desmond
    Nott, Louise M.
    Gibbs, Peter
    De Boer, Richard H.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] A functional polymorphism of TGFBR2 is associated with risk of breast cancer with ER+, PR+, ER+PR+ and HER2- expression in women
    Zhang, Mei
    Guo, Ling-Ling
    Cheng, Zhongqin
    Liu, Reng-Yun
    Lu, Yufeng
    Qian, Qian
    Lei, Zhe
    Zhang, Hong-Tao
    ONCOLOGY LETTERS, 2011, 2 (04) : 653 - 658
  • [50] A real-world evidence study of treatment patterns among patients with HER2-positive metastatic breast cancer
    Collins, Jenna
    Nordstrom, Beth
    Kwong, Jackie
    Murphy, Brian
    Pavilack, Melissa
    CANCER RESEARCH, 2021, 81 (04)
12345